Login / Signup

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.

Sudhir B MallaDavid J FisherEnric DomingoAndrew BlakeSylvana HassaniehKeara L RedmondSusan D RichmanMichael YoudellSteven M WalkerGemma E LoganAikaterina ChatzipliRaheleh AmirkhahMatthew Phillip HumphriesStephanie G CraigUltan McDermottMatthew T SeymourDion G MortonPhilip QuirkeNicholas P WestManuel Salto-TellezRichard D KennedyPatrick G JohnstonIan P M TomlinsonViktor Hendrik KoelzerLetitia CampoRichard S KaplanDaniel B LongleyMark LawlerTimothy S MaughanLouise C BrownPhilip David Dunnenull null
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
DDIR positivity does not predict improved response following oxaliplatin treatment in colorectal cancer. However, data presented here suggest the potential of the DDIR assay in identifying immune-rich tumors that may benefit from immune checkpoint blockade, beyond current use of MSI status.
Keyphrases
  • dna damage
  • immune response
  • oxidative stress
  • high throughput
  • dna repair
  • electronic health record
  • big data
  • dendritic cells
  • combination therapy
  • human health
  • data analysis